Ongoing research is exploring their long term impact when used primarily for weight management
T-P (tesamorelin to placebo) refers to the group of patients who received tesamorelin for Weeks 0-26 and were re-randomized to placebo for Weeks 26-52
ApoC-III is a key regulator of triglyceride metabolism, and human kinetic studies have shown that impaired catabolism of TRLs, linked to increased levels of plasma apoC-III, is the main determinant of plasma triglyceride levels in the population [8]
Unlike stand-alone Part D plans, Medicare Advantage plans with drug coverage (MAPD) have more flexibility in how they structure their formularies, and some have been more aggressive than others in adding GLP-1 drugs as an enrolled benefit in 2026
This oral medication helps regulate appetite and supports weight management when combined with healthy lifestyle changes
Chang H-Y et al (2018): Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes